Frequently Asked Questions
The market is segmented based on , By Condition (Chronic Liver Diseases, Hepatitis C, Nonalcoholic Steatohepatitis), Treatment (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Nonsurgical Tests, Transient Elastography, Liver Biopsy, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
.
The Global Liver Fibrosis Market size was valued at USD 16.45 USD Billion in 2021.
The Global Liver Fibrosis Market is projected to grow at a CAGR of 11.3% during the forecast period of 2022 to 2029.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
